Get the Stockscreener App
40.94
1.61%
-0.67
Cg Oncology Inc stock is traded at $40.94, with a volume of 372.20K.
It is down -1.61% in the last 24 hours and up +3.88% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$41.61
Open:
$41.34
24h Volume:
372.20K
Relative Volume:
0.39
Market Cap:
$3.30B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-32.23
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
-5.45%
1M Performance:
+3.88%
6M Performance:
+54.49%
1Y Performance:
+41.81%
1-Day Range:
$40.83
$42.40
1-Week Range:
$40.43
$44.01
52-Week Range:
$14.80
$46.01
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
40.94 | 3.36B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 26,000 CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
CG Oncology initiated with an Outperform at Wedbush - TipRanks
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story - Yahoo Finance
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Insider Monkey
CG Oncology (CGON) Valuation Check After Strong Late-Breaking Cretostimogene Bladder Cancer Trial Results - Sahm
Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market - TipRanks
CG Oncology (NASDAQ:CGON) Sets New 1-Year HighStill a Buy? - MarketBeat
Cg Oncology Inc. (CGON) Live Share Price, Invest From India - INDmoney
CG Oncology, Inc. (CGON) stock price, news, quote and history - Yahoo Finance UK
CG Oncology Incannounced topline data from Bond-003 cohort P and first results from Core-008 cohort A - marketscreener.com
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
CG Oncology Reports Promising Efficacy and Safety Data for Cretostimogene in High-Risk Non-Muscle Invasive Bladder Cancer Trials - Quiver Quantitative
CG Oncology (NASDAQ: CGON) posts 83.7% CR, no Grade 3+ AEs in NMIBC trial data - Stock Titan
Schroder Investment Management Group Acquires 155,737 Shares of CG Oncology, Inc. $CGON - MarketBeat
CG Oncology appoints Rossi to its Board of Directors - MSN
Will CG Oncology’s (CGON) Board Refresh and Cretostimogene Data Shape Its Bladder Cancer Strategy? - Sahm
Muscle Invasive Bladder Cancer Market to Reach New Heights - openPR.com
Midday Stock Roundup: Tilly’s, indie Semiconductor Up - Orange County Business Journal
CG Oncology (CGON) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
FY2025 EPS Estimates for CG Oncology Increased by Analyst - MarketBeat
A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements - Sahm
Will CG Oncology Inc. stock beat EPS estimatesMarket Sentiment Review & Proven Capital Preservation Tips - BỘ NỘI VỤ
Guidance Update: Will CG Oncology Inc. stock beat EPS estimates2025 Key Lessons & Proven Capital Preservation Tips - moha.gov.vn
Tejara Capital Ltd Purchases New Position in CG Oncology, Inc. $CGON - MarketBeat
Midday Stock Roundup: Eledon Up 4.8% - Orange County Business Journal
Intech Investment Management LLC Acquires 6,503 Shares of CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. $CGON Shares Purchased by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Increases Stake in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology Appoints Christina Rossi to Board - MSN
Why analysts upgrade CG Oncology Inc. stock2025 Analyst Calls & Long-Term Growth Stock Strategies - moha.gov.vn
CG Oncology (NASDAQ:CGON) Reaches New 12-Month HighHere's What Happened - MarketBeat
[Form 4] CG Oncology, Inc. Insider Trading Activity - Stock Titan
[Form 3] CG Oncology, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CG Oncology, Inc. Announces Board and Committee Changes - marketscreener.com
CG Oncology appoints Christina Rossi to board of directors By Investing.com - Investing.com Nigeria
Promising Developments in CG Oncology’s NMIBC Treatment Drive Buy Recommendation - TipRanks
CG Oncology appoints Christina Rossi to board as Simone Song resigns - Investing.com UK
CG Oncology appoints Christina Rossi to board as Simone Song resigns By Investing.com - Investing.com South Africa
CG Oncology appoints Christina Rossi to board of directors - Investing.com India
CG Oncology Announces Board Changes - TradingView
[8-K] CG Oncology, Inc. Reports Material Event | CGON SEC FilingForm 8-K - Stock Titan
CG Oncology Appoints Christina Rossi to Board of Directors - Quiver Quantitative
CG Oncology Announces New Board Member and Board Transition - The Manila Times
CG Oncology (NASDAQ: CGON) names Rossi to board amid BLA initiation - Stock Titan
CG Oncology, Inc. $CGON Position Lifted by Foresite Capital Management V LLC - MarketBeat
CG Oncology (NASDAQ: CGON) highlights BOND-003 and CORE-008 NMIBC data at SUO meeting - Stock Titan
Truist Financial Begins Coverage on CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. (CGON) Has a New Rating from Truist Financial - The Globe and Mail
CG Oncology Inc Stock Analysis and ForecastVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
TD Cowen Initiates Coverage of CG Oncology (CGON) with Buy Recommendation - MSN
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):